Fully oral regimen with decitabine and cedazuridine plus venetoclax: a new step forward for older or unfit patients with acute myeloid leukaemia
Mené sur 62 patients âgés atteints d'une leucémie myéloïde aiguë (âge médian : 78 ans), cet essai de phase II évalue l'efficacité, du point de vue du taux de réponse globale, et la toxicité d'un traitement combinant ASTX727 (décitabine et cédazuridine) et vénétoclax
Over the past 10 years, the therapeutic options for older or unfit patients with acute myeloid leukaemia have greatly improved thanks to the introduction of demethylating agents into clinical practice, first as monotherapy and then in combination with the BCL-2 inhibitor venetoclax (demethylating agents–venetoclax). Thanks to these drugs, the probability of overall survival of older and unfit patients with acute myeloid leukaemia (who are ineligible for intensive chemotherapy) has increased from a few weeks to months or even years, in responsive cases.